Diamedica Therapeutics Inc. · NASDAQ:DMAC
Diamedica Therapeutics — Corporate Update (November 2024)
6 slides from Diamedica Therapeutics's corporate update, Nov 13, 2024
Slide 1: ReMEDy2 Update
ReMEDy2 Update November 14, 2024 N/ Z DiaMedica AWS THERAPEUTICS Transforming Care for Stroke and Preeclampsia WY
Slide 2: Executive Summary
Executive Summary > Primary updates to ReMEDy2 AIS program: 1) Inclusion of patients who did not ‘respond’ to tPA/TNK (thrombolytic) — Anticipate strong treatment responses (strong DM199 response, low placebo response) and up to 50%+ increase in eligible patient poot 2.) Increase interim analysis sa
Slide 3: Why Including tPA/TNK Non-responders is Beneficial
1.tPA/INK ‘non-responders’ Why Including tPA/TNK Non-responders is Beneficial ) Potential Benefits: — tPA/TNK non-responders exhibited high treatment effect (low placebo response rate) in our Phase 2 ReMEDy1 trial + Potentially benefits interim analysis calculation and lowers final sample size — Lar
Slide 4: Updated Protocol Inclusion Criteria
‘ - ze 1. tPA/TNK ‘non-responders’ Updated Protocol Inclusion Criteria ) Ifthe participant has received tPA/TNK (thrombolytic) treatment for AIS. WaitingHours: within 4.5 hours of last known normal/AIS stroke onset, and at least 6 hours & ec ces + Risk of developing a bleed from tPA cut by after com
Slide 5: Potential Benefits of Increasing Sample Size
Potential Benefits of Increasing Sample Size Increases precision of final sample size determination — potential for significant cost/time savings ) The following actual simulation demonstrates the potential benefit of improving precision in determining the final sample size — Treatment effect (impro
Slide 6: ReMEDy2 Trial Summary of Updates
ReMEDy2 Trial Summary of Updates ) We believe adding non-responsive tPA/TNK may: vA Accelerate enrollment > increased per-site enrollment rates vo, Anticipate favorable treatment response > increases probability of clinical success and lower sample size Vv, Expand the commercial potential of DM199 i
DiaMedica Therapeutics — Corporate Update (November 2024) on 6ix